A Phase I, Open-label, Dose-escalating Study of the Safety or Percutaneous Intra-tumoral Injection of TG4023 (MVA-FCU1) Combined With Systemic Administration of 5-fluorocytosine in Patients With Primary or Secondary Hepatic Tumors

Trial Profile

A Phase I, Open-label, Dose-escalating Study of the Safety or Percutaneous Intra-tumoral Injection of TG4023 (MVA-FCU1) Combined With Systemic Administration of 5-fluorocytosine in Patients With Primary or Secondary Hepatic Tumors

Completed
Phase of Trial: Phase I

Latest Information Update: 29 Sep 2016

At a glance

  • Drugs TG 4023 (Primary) ; Flucytosine
  • Indications Liver cancer
  • Focus Adverse reactions; First in man; Proof of concept
  • Sponsors Transgene
  • Most Recent Events

    • 29 Sep 2016 Results (n=16) assessing feasibility and tolerability of TG4023 published in the Annals of Oncology (2016).
    • 18 Sep 2009 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top